title: [Use of high-energy intraluminal brachytherapy in radio- and radiochemotherapy for anal cancer].
abstract: Complete local response to radio- and chemoradiation for anal cancer was improved due to use of high-energy dosage of intraluminal brachytherapy (complete clinical regression (chemoradiation)--85.7%; combined irradiaton--75%). No signs of tumor progression have been reported in 20 survivors (median duration--21.6 months) (mean recurrence-free survival--12.5 months). Loco-regional relapse was in 4, local--2 patients. Intrapelvic lymph nodes were involved in 2 cases of previously morphologically confirmed regression of primary tumor. 18-month-long recurrence-free survival was in 86.3%, colostomy-free--91.6%. When combined with distant irradiation (+/-chemotherapy), brachytherapy is a relatively effective, safe and well tolerated procedure.
authors.forename: V A
authors.initials: VA
authors.lastname: Tarasov
authors.forename: I A
authors.initials: IA
authors.lastname: Larin
authors.forename: Iu K
authors.initials: IuK
authors.lastname: Sharov
authors.forename: A S
authors.initials: AS
authors.lastname: Bogdanovich
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Litvinov
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001005:Anus Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D001918:Brachytherapy / Q000379:methods; D017024:Chemotherapy, Adjuvant; D003125:Colostomy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis; D010865:Pilot Projects; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D016896:Treatment Outcome